Trial Outcomes & Findings for Web-based Addiction Treatment: Cultural Adaptation With American Indians (NCT NCT03363256)
NCT ID: NCT03363256
Last Updated: 2026-05-19
Results Overview
Each week was categorized as abstinent if the urine screen was negative and the self-report indicated no drug use and no heavy drinking days and not abstinent if either urine screen or self-report indicated drug use or heavy drinking. If the urine screen was missing, TLFB self-report data was used.
COMPLETED
NA
53 participants
12 weeks (following randomization)
2026-05-19
Participant Flow
Participant milestones
| Measure |
TAU + TES-NAV (Digital Intervention)
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN
|
TAU (Standard Outpatient Addiction Treatment)
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
|
|---|---|---|
|
Overall Study
STARTED
|
27
|
26
|
|
Overall Study
COMPLETED
|
27
|
26
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Web-based Addiction Treatment: Cultural Adaptation With American Indians
Baseline characteristics by cohort
| Measure |
TAU + TES-NAV (Digital Intervention)
n=27 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
|
TAU (Standard Outpatient Addiction Treatment)
n=26 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
|
Total
n=53 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
37.0 Years
STANDARD_DEVIATION 10.2 • n=30 Participants
|
40.2 Years
STANDARD_DEVIATION 10.3 • n=30 Participants
|
38.6 Years
STANDARD_DEVIATION 10.3 • n=60 Participants
|
|
Sex/Gender, Customized
Female
|
12 Participants
n=30 Participants
|
12 Participants
n=30 Participants
|
24 Participants
n=60 Participants
|
|
Sex/Gender, Customized
Male
|
14 Participants
n=30 Participants
|
14 Participants
n=30 Participants
|
28 Participants
n=60 Participants
|
|
Sex/Gender, Customized
Other
|
1 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=60 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
23 Participants
n=30 Participants
|
19 Participants
n=30 Participants
|
42 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=30 Participants
|
1 Participants
n=30 Participants
|
1 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
More than one race
|
4 Participants
n=30 Participants
|
6 Participants
n=30 Participants
|
10 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=30 Participants
|
4 Participants
n=30 Participants
|
6 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
25 Participants
n=30 Participants
|
22 Participants
n=30 Participants
|
47 Participants
n=60 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
PRIMARY outcome
Timeframe: 12 weeks (following randomization)Each week was categorized as abstinent if the urine screen was negative and the self-report indicated no drug use and no heavy drinking days and not abstinent if either urine screen or self-report indicated drug use or heavy drinking. If the urine screen was missing, TLFB self-report data was used.
Outcome measures
| Measure |
TAU + TES-NAV (Digital Intervention)
n=27 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
|
TAU (Standard Outpatient Addiction Treatment)
n=26 Participants
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
|
|---|---|---|
|
Consecutive Weeks of Drug/Alcohol Abstinence
|
2.0 Weeks
Interval 1.0 to 11.0
|
2.0 Weeks
Interval 1.0 to 6.0
|
Adverse Events
TAU + TES-NAV (Digital Intervention)
TAU (Standard Outpatient Addiction Treatment)
Serious adverse events
| Measure |
TAU + TES-NAV (Digital Intervention)
n=27 participants at risk
Standard outpatient psychosocial treatment for alcohol and drug use disorder at the study site (Treatment as Usual or TAU) plus Therapeutic Education System (digital intervention CRA + CM) adapted for AI/AN.
|
TAU (Standard Outpatient Addiction Treatment)
n=26 participants at risk
Standard outpatient psychosocial treatment for alcohol and drug use disorder (Treatment as Usual or TAU).
|
|---|---|---|
|
Injury, poisoning and procedural complications
Suicide attempt
|
0.00%
0/27 • From enrollment until the end of follow up (on average 24 weeks)
|
3.8%
1/26 • From enrollment until the end of follow up (on average 24 weeks)
|
Other adverse events
Adverse event data not reported
Additional Information
Aimee Campbell, PhD
New York State Psychiatric Institute
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place